Evaluating risuteganib for dry eye disease treatment

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.

The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.

Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.